KRAS and cancer: Numerous reports suggest that NQO1 elevation is a by-product of mutant K-RAS-driven Nrf2 overexpression in cancer cells, while others suggest that increased oxidative stress and inflammation drives NQO1 expression during tumorigenesis by activating NF-κB signaling through p53 inhibition49, 50, 51.